WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb. 3, 2006--Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved ROTATEQ(R) (rotavirus vaccine, live, oral, pentavalent), the only vaccine available in the U.S. to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children. ROTATEQ is an oral, three-dose vaccine given to infants between the ages of six to 32 weeks.
